Changes in metabolic syndrome status after initiation of antiretroviral therapy - Wikidata - wikimedia - TriplyDB

Changes in metabolic syndrome status after initiation of antiretroviral therapy

Changes in metabolic syndrome status after initiation of antiretroviral therapy

http://www.wikidata.org/entity/Q34674774

about

Non-communicable diseases and related risk behaviors among men and women living with HIV in Cambodia: findings from a cross-sectional study Immune activation and cardiovascular disease in chronic HIV infection.Metabolic Syndrome in People Living with Human Immunodeficiency Virus: An Assessment of the Prevalence and the Agreement between Diagnostic Criteria.Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study.Hypertension Is a Key Feature of the Metabolic Syndrome in Subjects Aging with HIV Prevalence of metabolic syndrome in HIV-infected patients naive to antiretroviral therapy or receiving a first-line treatment.Comorbidities associated with HIV and antiretroviral therapy (clinical sciences): a workshop report.Update and New Directions in Therapeutics for Neurological Complications of HIV Infections.

P2860

Q33909993-74C56025-F126-4BB5-8DAF-9B300EBCD480 Q36556082-5EB1F6D2-C61D-4362-816A-10CE42239E28 Q37723739-523215BA-7999-4D4A-96B6-F27F80CEEB1B Q38413429-416D9A25-6601-44FA-BF39-5471527C5E88 Q38821848-07BA2345-ABA0-46F7-BFCA-EB1985359479 Q38831718-BA2B9FA8-7D13-4AE0-BDF8-330570664227 Q38876754-DC9F2A4A-9857-4252-AC2F-B5E75E1543F1 Q38887659-3ACC39D7-A5B6-483B-B274-5A9AD9ADA5C0

P2860

Changes in metabolic syndrome status after initiation of antiretroviral therapy

http://www.wikidata.org/entity/Q34674774

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Changes in metabolic syndrome status after initiation of antiretroviral therapy

@ast

Changes in metabolic syndrome status after initiation of antiretroviral therapy

@en

Changes in metabolic syndrome status after initiation of antiretroviral therapy

@nl

type

label

Changes in metabolic syndrome status after initiation of antiretroviral therapy

@ast

Changes in metabolic syndrome status after initiation of antiretroviral therapy

@en

Changes in metabolic syndrome status after initiation of antiretroviral therapy

@nl

prefLabel

Changes in metabolic syndrome status after initiation of antiretroviral therapy

@ast

Changes in metabolic syndrome status after initiation of antiretroviral therapy

@en

Changes in metabolic syndrome status after initiation of antiretroviral therapy

@nl

P1433

Q34674774-2A6685B0-7413-468C-807C-DC75442B94A1

P1476

Q34674774-4CAE461A-C634-4C85-9BD1-6AD579BBD3B4

P2093

Q34674774-036854CC-3D72-437F-8EAB-2115067D38E4

Q34674774-1A12BD56-9727-4164-B715-A89CC678300A

Q34674774-4082C013-9EBF-4A8A-9945-650291A0F5F3

Q34674774-56897FB1-FE6F-4517-AB3D-D3B8E20C52BF

Q34674774-5ACE6984-5BBF-4FED-8B1B-65D6023BEF46

Q34674774-802DF9CC-277F-4BC2-98BA-8395843E302D

Q34674774-91F35976-5629-4ECA-A9C2-32A6C3988554

Q34674774-96C4A831-15D5-4292-A4D9-7C123FC5D559

Q34674774-BEA5FFF6-77D1-4150-862F-5DB9DD3C37E3

Q34674774-E4AC98D0-8E30-4DB6-8CDA-879BBCEA1AF6

P2860

Q34674774-07510A27-59CE-4956-90EC-60644ECF07E9

Q34674774-0832C4C9-9C9C-462C-BBB0-B17BE2450B61

Q34674774-1668989A-9E02-400D-A2DC-4F9A6FE9E9BC

Q34674774-1A58C510-6BEC-496B-892F-226A53563E61

Q34674774-297591C1-2D79-4743-BABC-CABD8CFF7079

Q34674774-2FCB16CA-8AA6-4FE8-A339-A5C79387717E

Q34674774-3E5F0841-2C2E-4C52-B16C-23F90C46B1BC

Q34674774-439A5B11-7DAF-4554-B769-5D0C08C82F73

Q34674774-481D8C49-49EB-4120-A895-6791D7A44A0C

Q34674774-4BE0163D-93B7-49DD-9D97-4101F48D31F5

P304

Q34674774-A7D0E761-9D04-4808-AC01-CBEBA299876A

P31

Q34674774-70FE4474-346E-4152-904F-8181B2924BD0

P356

Q34674774-4658CA5A-1660-4C91-8F33-283DCD2C0C83

P407

Q34674774-B8AD0C6A-A732-46D8-A56E-A0EB028D3D01

P433

Q34674774-5125B6EE-2DE5-49D0-BFD0-9865E311FFAF

P478

Q34674774-ED5647BA-83E0-412A-A6F7-8A58F0AC2A83

P577

Q34674774-8DDBDCEB-4E37-4D71-84EA-200D1ED5B9AE

P698

Q34674774-DD49D2E3-9D6D-4EE0-9F36-E2B10D5D373F

P921

Q34674774-3BC622DF-7F25-46AE-B1A5-19242F54A94A

Q34674774-9D7D3F88-6436-4371-8865-3402ED4C09CC

P932

Q34674774-02B8D47A-F031-4E51-8ACA-078830A3E43C

P356

QAI.0000000000000397

P1433

Journal of Acquired Immune Deficiency Syndromes

P1476

Changes in metabolic syndrome status after initiation of antiretroviral therapy

@en

P2093

Benjamin Atkinson

http://www.w3.org/2001/XMLSchema#string

Cecilia Shikuma

http://www.w3.org/2001/XMLSchema#string

David A Wohl

http://www.w3.org/2001/XMLSchema#string

Denise L Jacobson

http://www.w3.org/2001/XMLSchema#string

Grace A McComsey

http://www.w3.org/2001/XMLSchema#string

Jeffrey T Schouten

http://www.w3.org/2001/XMLSchema#string

Marshall J Glesby

http://www.w3.org/2001/XMLSchema#string

Richard Haubrich

http://www.w3.org/2001/XMLSchema#string

Supriya Krishnan

http://www.w3.org/2001/XMLSchema#string

Todd T Brown

http://www.w3.org/2001/XMLSchema#string

P2860

Metabolic and body composition effects of newer antiretrovirals in HIV-infected patients

Increasing rates of obesity among HIV-infected persons during the HIV epidemic

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy

Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment.

Hypertension and obesity in adults living in a high HIV prevalence rural area in South Africa.

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; Internat

New insights into the mechanism of low high-density lipoprotein cholesterol in obesity

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals

Nadir CD4+, religion, antiretroviral therapy, incidence of type 2 diabetes mellitus, and increasing rates of obesity among black Africans with HIV disease.

P304

73-80

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAI.0000000000000397

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25321179

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

metabolic syndrome

P932

4262682

http://www.w3.org/2001/XMLSchema#string